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Abstract
Introduction: Toll-like receptors (TLRs) are involved in both innate and adaptive immune responses and are likely to 
play a complex role in the pathogenesis of human rheumatoid arthritis (RA) and experimental arthritis. The objective of 
this study was to identify the key TLR in pristane-induced arthritis (PIA), a rat model for RA, and to clarify its roles in the 
initiation and maintenance of arthritis.
Methods: Arthritis in DA rats was induced by pristane and the severity was evaluated by macroscopic and microscopic 
score systems. Spleen TLR and cytokine expression was detected at different time points by real-time polymerase chain 
reaction (PCR) and flow cytometry. Polyinosine-polycytidylic acid (polyI:C, a ligand of TLR3) or TLR3 specific short-
hairpin RNA plasmid for RNA interference was administrated to PIA rats in vivo. Serum nitrogen oxide concentration 
was determined by Griess method, and tumor necrosis factor alpha (TNF-α) was determined by L929 biotest. In splenic 
macrophages, TLR3 expression was measured by flow cytometry. A rat macrophage cell line (NR8383) was stimulated 
by pristane, and anti-TLR3 antibody were used to block TLR3 pathway. TLR3 and cytokine expression in NR8383 were 
detected by real-time PCR.
Results: By screening the TLR expression profile in spleen of DA rats after pristane injection, we found that TLR3 was 
the most early and prominently upregulated TLR. Both TLR3 mRNA and protein expression of spleen were upregulated 
at 6 and 26 days after pristane injection. Furthermore, administration of polyI:C exacerbated, whereas RNA interference 
targeting TLR3 ameliorated, the arthritis. Particularly, TLR3 expression was induced in splenic macrophages of PIA rats, 
and also in the NR8383 cell line after pristane stimulation in a dose- and time- dependent manner. Upregulation of 
interferon beta (IFN-β) and TNF-α by pristane stimulation was blocked by anti-TLR3 antibody in NR8383.
Conclusions: TLR3 plays a pivotal role in the initiation and development of PIA which may dependent on macrophage. 
These findings are useful to understand the pathogenesis of RA and may provide an intriguing therapeutic 
opportunity for RA.
Introduction
Rheumatoid arthritis (RA) is an autoimmune chronic
inflammatory syndrome affecting 0.5 to 1% of the world
population, and is characterized by cellular proliferation
in the synovial lining and cartilage and bone destruction
of diarthrodial joints [1]. Genetic and serologic evidence
in both RA and experimental arthritis favors the involve-
ment of both innate and adaptive autoimmune processes
[2,3]. Toll-like receptors (TLRs) are pattern recognition
receptors, which form a bridge between innate and adap-
tive immune systems, and have been considered to be an
important factor in the development of RA [4].
TLRs are involved in activation of antigen-presenting
cells (APCs) by influencing the uptake and processing of
various exogenous and endogenous antigens [5]. Activa-
tion of TLRs in APCs not only leads to the upregulation
of the costimulatory molecule expression and cytokine
secretion [6,7], but also promotes the T cell polarization
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[8,9]. In addition, TLRs could orchestrate the function of
regulatory T cells [10,11].
TLRs are likely to play a complex role in RA, and cer-
tain TLRs exhibit a high expression, such as TLR2, 3, 4, 7
in synovium [12-15], TLR3 in fibroblast-like synoviocytes
(FLS) [14], TLR2, 4 in CD14+ macrophages and periph-
eral blood cells from RA [16]. Both exogenous and endog-
enous TLR ligands have been detected in synovia,
synovial fluids and sera of RA patients [14,17,18]. Impor-
tantly, these ligands are capable of stimulating FLS and/or
immunocytes via triggering TLRs to produce proinflam-
matory cytokines [12,19-24], and may also activate the
autoreactive T and B cells [25-27]. In particular, injection
of TLR2 and TLR9 ligands, peptidoglycan (PGN) and
CpG DNA, into articular cavities induces arthritis in mice
[28,29].
Based on the above-mentioned reasons, it seems that
TLRs play essential roles in the pathogenesis of RA. How-
ever, most studies on RA are descriptive and focus on
TLR2 and 4 in synovium. Thus, a systemic study about
TLR roles in the initiation of immune response of RA will
provide new insight for elucidating the pathogenesis of
RA. The TLR genes are highly conserved and using ani-
mal models should be reasonable to address the issue of
TLR roles in RA development.
Various animal models represent different or partly dif-
ferent disease processes of RA, and a few studies have
concerned TLR roles in the pathogenesis of arthritis.
TLR2 and 4 were reported to be involved in the chronic-
ity and erosive destruction of streptococcal cell wall
induced arthritis and spontaneous arthritis in IL-1 recep-
tor antagonist-knockout mice [8,30,31]. TLR4 takes part
in the initiation and progression of both autoantibody/
lipopolysaccharide (LPS)-triggered arthritis and serum
transferred arthritis [32,33]. It has also been suggested
that cathepsin K could ameliorate mycobacteria induced
arthritis in rats through suppression of TLR9 signaling in
dendritic cells (DCs) [34]. Of particular interest is the
pristane-induced arthritis (PIA) model as it is induced
with a single subcutaneous injection with a well-defined
compound lacking antigenic properties. The induced dis-
ease is joint specific and fulfills the clinical criteria of RA
[35,36]. Importantly, the arthritogenic adjuvant stimuli
may mimic such a trigger in humans represented by an
infectious agent or a non-specific inflammatory response.
It is known that pristane induces a strong innate immu-
nity through the triggering of IL-6 production [37], sug-
gesting that TLRs may participate in and mediate the
immune response. Altogether, the mechanism of TLRs
involved in experimental arthritis is not understood com-
pletely.
In the present study, we tried to find the key TLR in
arthritis development by screening the TLR1-9 expres-
sion profile in spleen from PIA rats. The results indicated
TLR3 showed a unique expression pattern compared
with other TLRs in spleen of PIA rats. And in PIA rats
treated with polyinosine-polycytidylic acid (polyI:C) or
RNA interference (RNAi) of TLR3, arthritis manifesta-
tions could be modified. Furthermore, TLR3 may exert its
influence in a macrophage-dependent manner. These
data illustrated the crucial role of TLR3 in the initiation
and development of PIA.
Materials and methods
Animals
DA rats were bred in a specific pathogen-free animal
house. Each group contained 8 to 10 rats at the age of 8 to
12 weeks. The experiments were approved by the Institu-
tional Animal Ethics Committee of the University (per-
mission No. 2006-21).
Induction and evaluation of arthritis
Arthritis was induced by a single subcutaneous injection
with 300 μl of pristane (ACROS Organics, Morris Plains,
NJ, USA) at the base of the rat's tail. Arthritis develop-
ment and severity were monitored every two to four days
by the perimeters of ankle and mid-paw, and a macro-
scopic scoring system as described [35].
Histopathological examination of joints
Left ankle joints of rats were sectioned and stained with
hematoxylin and eosin. Pathological severities were esti-
mated by extent of 10 items: a. thickness of synovium lin-
ing layer; b. pannus; c. synovium inflammatory cells; d.
angiogenesis; e. cartilage erosion; f. bone erosion; g. joint
ankylosis; h. change of overall articular structure; i. new
bone formation; and j. new cartilage formation. Each
pathological item was scored on a scale consisting of
score 0 (normal) to 3 (most severe). The maximum histo-
pathological scores of arthritis are 30 for each ankle. Syn-
ovitis was estimated by addition of item a. to d. scores;
joint destruction by e. to h. scores; joint healing by i. and
j. scores.
RNA quantitation
Total RNA was isolated with TRIzol® Reagent (Invitrogen,
Carlsbad, CA, USA), and cDNA was synthesized by First
Strand cDNA Synthesis Kit (Fermentas, Burlington, ON,
Canada). Real-time quantitative PCR was performed by
iQ5 (BIO-RAD, Hercules, CA, USA) with SYBR® Premix
Ex Taq™ II (TaKaRa, Ohtsu, Shiga, Japan) for TLR and
cytokine mRNA quantitation. And gene expression was
normalized by β-actin. The information on primers,
products and annealing temperatures were depicted in
Table 1.Meng et al. Arthritis Research & Therapy 2010, 12:R103
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Table 1: Information of primers for conventional PCR and Real-time PCR
Gene 
name
NCBI Accession 
No.
Sequence(5'-3') Size (bp) annealing 
temperature (°C)
TLR1 NM_001172120 forward CAGCAGCCTCAAGCATGTCTA
reverse CAGCCCTAAGACAACAATACAATAGAAGA 82 60
TLR2 NM_198769 forward CTCCTGTGAACTCCTGTCCTT
reverse AGCTGTCTGGCCAGTCAAC 74 60
TLR3 NM_198791 forward GATTGGCAAGTTATTCGTC
reverse GCGGAGGCTGTTGTAGG 205 54
TLR4 NM_019178 forward GATTGCTCAGACATGGCAGTTTC
reverse CACTCGAGGTAGGTGTTTCTGCTAA 135 54
TLR5 XM_001063885 forward GGGCAGCAGAAAGACGGTAT
reverse CAGGCACCAGCCATCCTTAA 61 60
TLR6 NM_207604 forward AGAACCTTACTCATGTCCCAAAAGAC
reverse AGATCAGATATGGAGTTTTGAGACAGACT 79 60
TLR7 NM_001097582 forward GTTTTACGTCTACACAGTAACTCTCTTCA
reverse TTCCTGGAGGTTGCTCATGTTTT 75 60
TLR8 NM_001101009 forward GGGGTAACACACCGTCTA
reverse GTCAAGGCGATTTCCACT 150 60
TLR9 NM_198131 forward CCGAAGACCTAGCCAACCT
reverse TGATCACAGCGACGGCAATT 70 60
TNF-α NM_012675 forward TCAGCCTCTTCTCATTCCTGC
reverse TTGGTGGTTTGCTACGACGTG 203 60
IL-6 NM_012589 forward AAGAAAGACAAAGCCAGAGTC
reverse CACAAACTGATATGCTTAGGC 263 60
IFN-γ NM_138880 forward CCCTCTCTGGCTGTTACTGC
reverse TTTCGTGTTACCGTCCTTTTG 149 54
IFN-β NM_019127 forward CTTGGGTGACATCCACGACTAC
reverse GGCATAGCTGTTGTACTTCTTGTCTT 92 54
β-actin NM_031144 forward GAGGGAAATCGTGCGTGAC
reverse GCATCGGAACCGCTCATT 157 60
gfp - forward GGCACCGATTTCAAGGAG
reverse CGCCGATGGGGGTATTCT 190 54
Fluorescence-activated cell sorting (FACS) analysis of TLR 
expression in splenocytes
Three tubes containing 106 splenocytes for cell surface
TLR detection were incubated with TLR2, TLR3 and
TLR4 antibodies (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) respectively. In the other tube for intracellular
TLR3, the cells were fixed and perforated before TLR3
antibody incubation. For detection of macrophage TLR3,
two tubes containing 106  splenocytes were incubated
with HIS36-PE (anti-rat macrophage, eBioscience, San
Diego, CA, USA) firstly. And for cell surface TLR3 detec-
tion, the cells were incubated with TLR3 antibody at the
same time. For intracellular TLR3 detection, the cells in
the other tube after His36-PE staining, were fixed and
perforated before TLR3 antibody incubation. The cells
from both tubes were incubated with goat anti-rabbit
IgG-biotin followed by streptavidin-cychrome. Cells were
analyzed by using a FACScanto (Becton Dickinson,
Franklin Lakes, NJ, USA), and datum analysis was per-
formed using FlowJo software (Tree Star, Ashland, OR,
USA).
Administration of TLR ligands to PIA rats
Thirty-six rats were randomly divided into four groups.
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μl phosphate buffered saline (PBS) only. Other groups
were injected subcutaneously with 300 μl pristane, then
administered subcutaneously with 150 μl saline contain-
ing 100 μg polyI:C (Amersham Biosciences, Piscataway,
NJ, USA) in the polyI:C group, 50 μg LPS (Sigma-Aldrich,
St. Louis, MO, USA) in the LPS group, and none in the
saline group, respectively, at two days after pristane injec-
tion [38,39].
Cell transfection and treament with TLR3 RNAi in vivo
The target sequences of TLR3 gene are GAA TCA CAT
CTC GAA GAT A, called as shRNA1-TLR3; CTC TCA
ATT TAA CGA AGA A, as shRNA2-TLR3; ACC TCG
ACC TCA CAG AGA A, as shRNA3-TLR3; and CCT
GAC AGA GCT CCA TCT A as shRNA4-TLR3. The
sequence of negative control shRNA is TTC TCC GAA
CGT GTC ACG T. These different short-hairpin RNA
(shRNA) sequences were inserted into pGCsilencer™ U6/
Neo/GFP/RNAi plasmid (Genechem, Shanghai, China).
The plasmids were extracted with E.Z.N.A.™ Endo-free
Plasmid Maxi Kit (Omega Bio-tek, Doraville, GA, USA),
and NR8383 cells were transfected with Lipofectamin™
2000 (Invitrogen). TLR3 expression of cells was detected
by RT-PCR after 24 hours and by FACS after 48 hours.
DA rats randomly divided into three groups were injected
subcutaneously with 300 μl pristane. At one day before
pristane injection, and 5, 11 and 17 days after pristane
injection, 1 ml of saline was injected peritoneally into the
rats in the saline group; 50 μg shRNA3-TLR3 in 1 ml of
saline in the shRNA-TLR3 group; and 50 μg negative con-
trol shRNA in 1 ml of saline in the shRNA-NC group
[40,41]. At 20 days after pristane injection (d20), GFP
mRNA expression was detected by RT-PCR to monitor
the plasmid presence in spleen (Primer information was
depicted in Table 1). And TLR3 mRNA expression in the
spleen was detected by real-time quantitative PCR for
determination of the RNAi effectiveness.
Measurement of NO concentration
Serum protein was removed, and NO3
- was reduced to
NO2
- by using cadmium filings. Then NO2
- was measured
by a microplate assay method based on the Griess reac-
tion.
Measurement of TNF-α concentration
The mouse fibroblast cell line, L929, was cultured in
RPMI 1640 (Hyclone, Logan, UT, USA) containing 10%
FCS. Ten thousand cells in 100 μl were incubated for 24
hours. Then sera containing 1 mg/ml actinomycin D were
added to replace the original medium. After an 18-hour
incubation, cell viability was evaluated by the methyl thi-
azolyl tetrazolium method. Rat recombinant TNF-α
(Bender MedSystems Inc., Burlingame, CA, USA) was
used as the standard.
Stimulation of macrophages with pristane
The rat macrophage cell line, NR8383, was cultured in F-
12 K medium (Sigma-Aldrich) with 20% FBS (Hyclone).
Emulsion of pristane was made by repeated aspiration
with PBS. Half-million cells per well were put in a six-well
plate, then a 50 μl pristane emulsion was added in the cul-
ture medium. The theoretical pristane concentration is
0.1, 1, 10, 100 μM, 1 mM and 10 mM, calculated on the
basis of original volume of pristane employed. The cells
were collected after 8, 24, 48 and 72 hours of stimulation.
TLR3 blockade assay in NR8383
NR8383 were seeded in six-well plates at a density of half-
million per well. In the TLR3 Blockade assay, cells were
treated with anti-TLR3 or isotype control antibodies at a
concentration of 20 μg/ml for 90 minutes before being
stimulated with 100 μM pristane or 10 μg/ml polyI:C.
The cells were collected after 24 hours' stimulation.
Statistics
Quantitative data were expressed as means ± SEM. The
statistical analysis of differences between experimental
groups was performed by Mann-Whitney U test or Stu-
dent's T test. Correlation analysis was performed by Pear-
son test. P < 0.05 was considered significant.
Results
TLR3 expression of spleen exhibits a remarkable increase in 
the PIA rat model
Arthritis-susceptible DA rats were given a single subcuta-
neous injection of pristane known to induce arthritis
within two weeks [35]. The spleens were isolated and
analyzed for mRNA expression at different time points.
The results showed that only TLR3 mRNA expression
was upregulated as early as six days after pristane injec-
tion (d6) (Figure 1a). TLR1-4 and TLR8 were significantly
expressed at 26 days after pristane injection (d26) (Figure
1a). However, TLR5, 6, 7, 9 did not show a significant
change after pristane injection. Another independent
experiment was performed with more time points, 2 and
12 (d12) days after pristane injection. TLR3 expression
increased dynamically and progressively with the arthritis
initiation and development. It was significantly upregu-
lated at d6 and d26, and had a high level at d12 (Figure
1b). IFN-β, known to be triggered by TLR3, was upregu-
lated at d6 and d26 (Figure 1c). Of the proinflammatory
cytokines, TNF-α and IL-6 mRNA expression only
increased at d6 (Figure 1c). And IFN-γ mRNA expression
at d6 and d26 had no difference comparing with control
group (d0).
Based on the expression at mRNA level, we determined
the protein expression of TLR2, 3 and 4 in the spleens of
PIA rats by flow cytometric staining. The results showed
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increased significantly at d6 and d26, while that of intrac-
ellular TLR3 positive cells and cell surface TLR2 and 4
positive cells increased significantly only at d26 (Figure
1d).
The administration of TLR3 ligand increases arthritis 
severity
The pristane pre-injected rats were treated with ligands
of TLR3 (polyI:C), TLR4 (LPS) and saline, respectively.
The clinical score of the polyI:C group showed significant
increase compared with the saline group and the LPS
group from 15 days after pristane injection, and maxi-
mum clinical score of the polyI:C group consistently had
a significant difference compared with other groups (Fig-
ure 2a). Maximum perimeters of hind paw and ankle also
increased in the polyI:C group (Figure 2a). Serum NO
concentration increased significantly in all PIA groups, in
particular in the polyI:C group (Figure 2b), but there are
no differences among all pristine-treated groups. TNF-α
concentration in the polyI:C group increased significantly
compared with other groups (Figure 2b).
Histopathologically, polyI:C administration aggravated
the pathologic changes with abundant inflammatory cell
infiltrates and bone destruction (Figure 2c). PolyI:C
group showed significant differences with the LPS group
and the saline group in the pathological score of synovitis,
joint destruction, new bone and cartilage formation (Fig-
ure 2d). Meanwhile, the total pathological score of
polyI:C group had significantly increased compared with
other groups (Figure 2d). All results from the clinical,
serological and pathological data indicated that TLR3
ligand administration to the PIA rats could make the dis-
ease more severe, and further highlighted the important
role of TLR3 in PIA development. Then RNAi of TLR3 in
vivo was performed to convince the authors that TLR3 is
essential in PIA pathogenesis.
The RNAi of TLR3 significantly ameliorates PIA in rats
NR8383 macrophages were transfected with four differ-
ent TLR3 shRNA plasmids to determine whether the
expression of TLR3 could be downregulated. Results
from RT-PCR and flow cytometric staining showed that
shRNA3-TLR3 most efficiently downregulated TLR3
mRNA and protein expression (Figure 3a, b). The plas-
mids, shRNA3-TLR3 (shRNA-TLR3 group) and shRNA-
NC (shRNA-NC group, as a negative control), were
applied to PIA rats in vivo. The GFP gene in the plasmid
treatment groups, except for the saline group, was suc-
cessfully amplified by RT-PCR (Figure 3c), which showed
that plasmids with peritoneal injection in rats could accu-
mulate in the spleen. And TLR3 mRNA expression in the
spleen of the shRNA-TLR3 group was significantly lower
than that of the shRNA-NC group at d20 (Figure 3d). The
clinical score of the shRNA-TLR3 treated rats was lower
than that of the shRNA-NC and saline treated rats from
16 days after pristane injection (Figure 3e). The PIA onset
day of the shRNA-TLR3 group was later than that of the
other two groups (Figure 3e). The shRNA-TLR3 group
showed a significantly lower maximum score compared
with the other two groups (Figure 3e). The NO concen-
tration in the shRNA-TLR3 group was significantly lower
than that of the saline group (Figure 3f). Results indicated
that the knockdown of TLR3 expression can ameliorate
the disease after pristane injection in rats.
TLR3 expression was induced in macrophages with 
pristane stimulation
TLR3 expression in splenic macrophages was detected by
flow cytometric staining in PIA rats. The mean fluores-
cence intensity (MFI) of cell surface TLR3 positive cell
increased markedly at d6 and the proportion increased
significantly at d26, although the intracellular TLR3
expression showed no change after pristane injection,
suggesting that the role of TLR3 in the pathogenesis of
the disease seems to be associated with the high expres-
sion on the macrophage membrane (Figure 4a).
To confirm the role of pristane on TLR3 expression
upregulation in macrophages, we stimulated NR8383, a
rat macrophage cell line, with pristane. We found that
TLR3 mRNA expression was increased in a dose-depen-
dent manner after pristane stimulation, and reached the
peak at 1 mM pristane (Figure 4b). In contrast, TLR4
mRNA expression did not show a dose-dependent ten-
dency. TLR3 expression was induced already at 8 hours
after pristane stimulation, and was highest at 24 hours
(Figure 4c). IFN-β mRNA expression also showed a pat-
tern similar to TLR3, and increased significantly in the
group stimulated at 24 and 48 hours (Figure 4d). TNF-α
mRNA expression increased significantly at 24 and 48
hours (Figure 4d). However, as NR8383 were pretreated
with anti-TLR3 antibody, the upregulation of IFN-β and
TNF-α expression stimulated by both pristane and
polyI:C was inhibited significantly (Figure 4e). The result
indicated that in macrophages pristane certainly orches-
trated high TLR3 mRNA expression, which activated the
downstream cytokine pathway.
Discussion
A single subcutaneous injection of pristane in DA rats
leads to chronic relapsing arthritis similar to RA in
humans. We now show that pristane injection also leads
to an upregulated expression of TLRs, in particular TLR3.
TLR3 was found to play a critical role in the development
of arthritis as an injection of TLR3 ligand enhanced
arthritis and downregulation of TLR3 through treatment
with RNAi alleviated arthritis. And TLR3 expression was
induced with pristane stimulation particularly in mac-
rophages.Meng et al. Arthritis Research & Therapy 2010, 12:R103
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PIA is a T cell dependent disease, which can be trans-
ferred with αβT cells [42], and there is no evidence so far
arguing for a pathogenic role of B cells. In the human dis-
ease it is clear at present that many patients benefit from
depletion of B cells through injection of antibodies to
CD20. In contrast, in PIA antibodies to citrullinated pro-
teins are not evoked and there is no evidence for patho-
genic antibodies mediating the disease, unlike in the
collagen-induced arthritis model. However, the immune
response in PIA also shows some striking similarities
with RA since rheumatoid factors and antibodies to RA33
are produced in both diseases [43]. Importantly, a strong
activation of an innate response is apparent in both RA
and PIA, although in RA it has been possible to analyze
the response only in already established disease. In RA
synovial tissues a strong overexpression of TLR3 and 4
has been reported, whereas isolated macrophages show
high expression of TLR2 and 4 [13,16]. But there has been
no study on TLRs in the PIA rat model so far.
A subcutaneous injection of mineral oil or phytol,
structurally similar to pristane, leads to an accumulation
of oil at the injection site but also a rapid spread of small
volumes to draining lymph nodes and subsequently
spreads systemically, reaching the spleen [44,45]. Previ-
ous studies have shown that T cells isolated from spleens,
less than eight days after pristane injection, transfer
severe arthritis, showing that the critical arthritogenic
change induced by pristane is present in the spleen [42].
Therefore we selected the spleen to study the innate
immune reaction after pristane injection.
Screening TLR mRNA expression at different time
points after pristane injection, we found that expression
of TLR1, 2, 3, 4 and 8 in the spleen is upregulated in the
development stage of arthritis (d26), which is consistent
with previous studies from arthritis models and RA
Figure 1 TLR and cytokine expression profile of spleen from DA rats with pristane-induced arthritis. The mRNA expression (a) of TLR1-9 at d0, 
6 and 26, (b) of TLR3 at d0, 2, 6, 12 and 26, (c) and of cytokines at d0, 6 and 26 in spleen of rats was measured by Real-time quantitative PCR (n = 8 to 
10 for each time point). Relative mRNA expression was compared with β-actin. Protein expression of TLRs in spleen was detected by FACS at d0, 6 and 
26 (n = 3 for each time point). The positive splenocyte proportion (d) of cell surface and intracellular TLR3, and cell surface TLR2 and TLR4 is showed 
in the course of arthritis. Data were collected after correction for isotype-matched IgG control. Values are shown as means ± SEM. Levels of significance 
between the pristane treated group (6, 26 days) and untreated group (0 day) were calculated by using Mann-Whitney U test (* P < 0.05, ** P < 0.01, 
*** P < 0.001).Meng et al. Arthritis Research & Therapy 2010, 12:R103
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Figure 2 More severity, higher serology index and increased histopathological scores of PIA caused by polyI:C treatment. The arthritis clini-
cal indexes (a) including clinical score, max clinical score, onset day, mid-paw perimeter, ankle perimeter; and serum NO and TNF-α concentration at 
d26 (b) were compared among the polyI:C, LPS and saline groups. (c), In representative histological images of ankle joints, the ankle joints in the con-
trol group and PIA groups treated with saline or ligands were stained by H&E. (d), For the histological analysis of synovitis, joint destruction, new bone 
and cartilage formation and the total histological index, the various scores were quantified among PIA groups treated with saline and ligands. Data 
are presented as means ± SEM. * represents the comparison between ligands treated groups and saline group in A and D, or between ligands treated 
groups and control group in B. But # between ligands treated groups as marked. Levels of significance were calculated using Mann-Whitney U test (n 
= 9 for each group, */# P < 0.05, **/## P < 0.01, ***/### P < 0.001).Meng et al. Arthritis Research & Therapy 2010, 12:R103
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Figure 3 Attenuated severity and reduced and a serum NO concentration of PIA caused by RNAi of TLR3 in vivo. Four TLR3-shRNA plasmids 
and a negative control plasmid were transfected into NR8383 cells. mRNA ((a), 24 hours after transfection) and protein ((b), 48 hours after transfection) 
expression levels of TLR3 were detected by RT-PCR and FACS respectively, and shRNA3-TLR3 (shRNA-TLR3) shows the best RNAi efficacy. The plasmids 
of shRNA-TLR3 and shRNA-NC were used to treat PIA rats, and GFP mRNA expression (c) in plasmid treatment groups except in the saline group was 
successfully amplified by RT-PCR. (d), TLR3 expression of the spleen at d20 was detected by Real-time quantitative PCR. Relative mRNA expression was 
compared with the housekeeping gene β-actin. The arthritis clinical indexes (e) including clinical score, max clinical score and onset day; and serum 
NO concentration at d26 (f) were compared among three group PIA rats treated with saline, shRNA-NC and shRNA-TLR3, respectively. Data are pre-
sented as means ± SEM. * represents the comparison between the shRNA treated group and the saline group, and # between the shRNA-TLR3 and 
shRNA-NC groups. Levels of significance were calculated by using Mann-Whitney U test (n = 8 for each group, */# P < 0.05).Meng et al. Arthritis Research & Therapy 2010, 12:R103
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Figure 4 TLR3 expression was induced in macrophages with pristane stimulation. In splenic macrophages, TLR3 protein expression was detect-
ed by FACS at 0, 6 and 26 days after pristane injection. The proportion and mean fluorescence intensity (MFI) of cell surface and intracellular TLR3 were 
detected on His36+ (anti-rat macrophage) gated TLR3+ cells from splenocytes, and representative histograms (a) are showed in the course of arthritis. 
Data were collected after correction for isotype-matched IgG control. NR8383 cells were stimulated with a series of concentrations of pristane (0.1 μ, 
1 μ, 10 μ, 100 μ, 1 m, 10 mM as theoretical pristane concentration), and TLR3 and TLR4 mRNA expression was detected at 48 hours after stimulation 
(b). The expression of TLR3 increased with a raised dosage of pristane (r2 = 0.78) by Pearson correlation analysis. With 100 μM pristane stimulation, 
TLR3 (c) and IFN-β, TNF-α (d) mRNA expression was measured at 0, 8, 24, 48 and 72 hours. (e) NR8383 pretreated with anti-TLR3 or isotype control 
antibodies were stimulated by 100 μM pristane or 10 μg/ml polyI:C, and IFN-β, TNF-α mRNA expression was measured at 24 hours. mRNA expression 
level was detected by Real-time quantitative PCR, and data are presented as means ± SEM of four replicated determinations from three independent 
experiments. * represents the comparison with the control group (Blank in B and E, and 0 hour in C and D), and levels of significance were calculated 
by using Student's T test (* P < 0.05, ** P < 0.01, *** P < 0.001).Meng et al. Arthritis Research & Therapy 2010, 12:R103
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patients [20,22,23,46]. A compelling TLR is TLR3 as it
was highly expressed uniquely in the early phase, and
increased progressively with the development of the dis-
ease. It has been reported that TLR3 is overexpressed in
synovial tissue from both early and longstanding RA
[12,13]. A possible pathogenic role of the upregulated
T L R 3  c o u l d  b e  t h a t  i t  r e c o g n i z e s  R N A  r e l e a s e d  f r o m
necrotic synovial fluid cells, and then activates RA syn-
ovial fibroblast [14]. TLR3 combined with TLR4, TLR7/8
is also involved in the regulation of DC activation and
cytokine production in RA patients [12]. It indicates that
TLR3 in the spleen may play a vital role in PIA. To exam-
ine whether the observed TLR overexpression has func-
tional consequences, downstream cytokines of TLR
pathway, such as TNF-α, IL-6, IFN-γ and IFN-β mRNA
expression in the spleen were determined. IFN-β expres-
sion was found to increase at both d6 and d26, whereas
TNF-α and IL-6 expression only increased at d6, and the
IFN-γ expression level did not change. These proinflam-
matory cytokines are known to be regulated by many
TLRs via several intracellular pathways but are mainly
associated with NF-κB. TLR3 and possibly TLR4 activate
interferon regulatory factor 3 which regulates IFN-β
expression [47]. By flow cytometric staining we con-
firmed high TLR3 protein expression in splenocytes. The
expression of TLR3 on splenocyte surfaces increased at
d6 and d26, reflecting its mRNA expression pattern.
Based on the experimental data from the gene expres-
sion profile and TLR2, 3, 4 protein expression during the
disease course, we suggest that TLR3 plays an important
role in the pathogenesis of PIA. Such a role could be con-
firmed through in vivo experiments with TLR3 ligands
and RNAi. In a previous study, intra-articular treatment
with polyI:C to rats caused a rapid and strong synovitis
[48], which suggested the important role of TLR3 signal-
ing in arthritis pathogenesis. And in our research, the sys-
temic treatment with polyI:C synergism with pristane
showed that TLR3 ligand could exacerbate arthritis. This
d o m i n a n t  r o l e  o f  t h e  T L R 3  l i g a n d  w as  a l s o  p r o v e d  b y
pathology of the PIA rat ankles. The possible mechanism
of polyI:C's effect on PIA could be that more TLR3 is
activated by polyI:C, which triggers more severe inflam-
matory reaction in joints. Meanwhile, the results also
emphasize the important roles of the ligand in arthritis
pathogenesis. But at present, it is still not defined which
e n d o g e n o us  l i g a n d  o f  T LR 3  pa rt i ci pa t e s  i n  P IA.  T h u s,
priority should be given to exploring the probable ligand
and investigating its roles in arthritis.
A crucial role of TLR3 in the PIA pathogenesis could
also be confirmed by treatment with RNAi in vivo. The
shRNA plasmids did not show any immunostimulatory
effect in vivo because the shRNA-NC group shows no dif-
ferences from the saline group in all indexes. The results
indicated that the RNAi of TLR3 participated in the initi-
ation of PIA significantly delayed the onset day and
decreased arthritis severity. NO concentration of shRNA-
TLR3 group was also significantly lower than that of the
shRNA-NC and saline groups. The result validates the
importance of TLR3 in PIA, however, the ligands and the
functional consequences of TLR activation in PIA are not
yet fully understood.
TLR3 expresses mainly on DC for humans but on mac-
rophages for mice [49]. It has been found that mac-
rophages are involved in the pathology of K/BxN serum-
induced arthritis [50]. Macrophage-derived reactive oxy-
gen species (ROS) participate in T cell selection, matura-
tion and differentiation, and also mediate protection
against arthritis by suppressing T cell activation [51]. In
addition, macrophages stimulated by excessive interleu-
kin-15 may activate the characteristic autoreactive CD4+
T cells in RA [27]. The increased macrophage activation
may be mediated by TLRs in RA or other autoimmune
inflammatory diseases [16,52]. All findings indicate mac-
rophages are a main player in the development of arthri-
tis. We found that TLR3 positive macrophages were
increased in the spleen of PIA rats, and cell surface TLR3
showed high expression in the initiation stage of arthritis.
It suggests that cell surface TLR3 on macrophage, but not
the intracellular expression, exerts a crucial influence on
the pathogenesis of PIA.
Using a rat macrophage cell line, NR8383, we could
confirm that TLR3, but not TLR4, was upregulated after
stimulation with pristane, which excludes LPS contami-
nation in the experiment. Furthermore, the mRNA
expression of IFN-β, the main downstream cytokine of
TLR3, also increased with the same tendency as that of
TLR3. The increase of IFN-β and TNF-α was inhibited by
anti-TLR3 antibody, suggesting that this induction was
TLR3 dependent. The above mentioned data indicate
TLR3 and its downstream molecules in macrophage were
activated by pristane, and then took part in the pathogen-
e s i s  o f  P I A .  M o r e  T L R 3  e x p r e s s i o n  o n  m a c r o p h a g e s
could affect the cell function, such as the capacity of anti-
gen presentation, ROS production, phagocytosis, secre-
tion of cytokines and chemokines and so on.
Macrophages with upregulated TLR3 may affect the bal-
ance of Th1/Th2 and the activations of autoreactive T
cells and B cells [25,42].
However, it is still unclear how pristane induces TLR3
expression. The interaction between TLR and alkanes like
pristane is not completely known. It is reported that oxi-
dized alkane polymers induced activation of the TLR1/2
pathway as its ligands. And pristane could augment the
effect of TLR7 ligands but does not directly activate
TLR7. In a PIA rat model, further study is needed as to
whether pristane or its metabolism products are the
ligand of TLR3, or if it induces TLR3 by another pathway.
Further studies are also needed to understand underlyingMeng et al. Arthritis Research & Therapy 2010, 12:R103
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mechanisms as to how TLR3 activates joint-specific auto-
immune T cells via macrophages.
Conclusions
In summary, we screened TLR and downstream cytokine
expression in the spleen of PIA rats, and found that only
TLR3 expression was increased at the initiation stage.
Regulating TLR3 by using ligand or shRNA in vivo could
directly aggravate or relieve symptoms of arthritis. TLR3
may play its role via splenic macrophage, since it had a
high expression on macrophages after pristane injection
in vivo. And the induction of TLR3 was specifically due to
pristane stimulation in macrophage cell lines with a dose-
and time- dependent manner. These findings are not only
useful in understanding the underlying pathogenesis of
RA, but also provide a valuable clue for other immuno-
logical disease research.
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